Biotricity and BioAffinity Technologies Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
Biotricity and BioAffinity Technologies Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
ORLANDO, FL / ACCESSWIRE / July 12, 2024 / RedChip Companies will air interviews with Biotricity, Inc. (Nasdaq:BTCY) and bioAffinity Technologies, Inc. (Nasdaq:BIAF) on the RedChip Small Stocks, Big Money show, a sponsored program on Bloomberg TV, this Saturday, July 13, at 7 p.m. Eastern Time (ET). Bloomberg TV is available in an estimated 73 million homes across the U.S.
RedChip公司將在本週六晚7點（東部時間）在Bloomberg TV贊助的《Small Stocks, Big Money》節目上播出與Biotricity，Inc.（Nasdaq:BTCY）和bioAffinity Technologies，Inc.（Nasdaq:BIAF）的訪談。Bloomberg TV在美國大約有7300萬戶家庭可以收看。
Access the interviews in their entirety at:
Soligenix:
Biotricity:
bioAffinity Technologies:
Biotricity:
bioAffinity Technologies的總裁兼首席執行官Maria Zannes將在Bloomberg TV的RedChip節目上提供公司更新。bioAffinity Technologies是早期癌症診斷領域的新興參與者。其旗艦產品CyPath Lung通過分析肺部微環境提高早期肺癌的檢測效率。這種非侵入性的測試具有高靈敏度、特異性和準確性。肺癌往往在達到晚期時才被發現，治療方案的效果不佳。早期檢測可提高生存率並降低醫療費用。隨着商業化計劃的推廣，包括德克薩斯州的試點計劃和美國國防部爲進行持續性研究而購買測試，公司已爲創業板做好了準備。到2030年，肺癌篩查市場預計將達到57億美元。公司正在開發由人工智能驅動的自動化數據分析來協助非侵入性診斷慢性阻塞性肺疾病和哮喘的細胞流式分析平台，這兩種疾病的全球市場預計將在2027年達到82億美元。公司擁有廣泛的美國和國際專利。內部人士對公司的持股力度非常強，持股比例爲39%並且持續增加。擁有高度經驗的領導團隊，bioAffinity Technologies在早期癌症診斷領域具備推動創新的優勢。
In an exclusive interview, Dr. Waqaas Al-Siddiq, Founder and CEO of Biotricity, will share insight into the company's innovative portfolio of cardiac monitoring solutions, which includes the FDA-cleared Bioflux and Biocore devices, targeting a total addressable market of $35 billion. With its solutions utilized daily by cardiologists across 34 states and 500 centers, Biotricity has captured an 8% market share in cardiology, bolstered by high retention rates of approximately 99% and a recurring revenue base that boasts strong LTV-to-CAC ratios. Biotricity is on a clear path to profitability and expects to be EBITDA positive before the end of 2024.
在一次獨家採訪中，Biotricity的創始人兼CEO Dr. Waqaas Al-Siddiq將分享該公司創新的心臟監測解決方案組合的見解，其中包括FDA批准的Bioflux和Biocore設備，目標總市場價值達350億美元。由34個州和500箇中心的心臟病專家每天使用其解決方案，Biotricity在心臟病領域佔據了8%的市場份額，支持率約爲99%，並擁有一個循環收入基礎，LTV-to-CAC比率強勁。Biotricity正在走向盈利，並預計在2024年底之前實現EBITDA盈利。
Maria Zannes, President and CEO of bioAffinity Technologies, appears on the RedChip Small Stocks, Big Money show on Bloomberg TV to provide a corporate update. bioAffinity Technologies is an emerging player in early-stage cancer diagnosis. Its flagship product, CyPath Lung, improves detection of early-stage lung cancer by analyzing the lung microenvironment. The noninvasive test has shown high sensitivity, specificity and accuracy. Lung cancer often goes undetected until it reaches late-stage when treatment options are less effective. Early detection increases survival and reduces medical costs. With commercialization underway, including a pilot program in Texas and the US DoD's purchase of tests for ongoing research, the Company is well-poised for growth. The lung cancer screening market is projected to reach $5.7 billion by 2030. The Company's flow cytometry platform, enhanced by AI-driven automated data analysis, is being developed to aid in noninvasive diagnosis of COPD and asthma, which have a combined global market expected to reach $8.2 billion by 2027. The Company holds extensive U.S. and international patents. Insiders show strong support for the Company with ownership at 39% and increasing. With a highly experienced leadership team, bioAffinity Technologies is well-positioned to drive innovation in early-stage cancer diagnosis.
Maria Zannes，bioAffinity Technologies的總裁兼CEO，出現在Bloomberg TV的RedChip Small Stocks，Big Money show上，提供公司更新。bioAffinity Technologies是早期癌症診斷的新興參與者。旗艦產品CyPath Lung通過分析肺部微環境改善早期肺癌的檢測。這種無創檢測具有高靈敏度、特異性和準確性。肺癌通常在達到晚期時才能被檢測出來，此時治療選項不太有效。早期檢測可以提高生存率並降低醫療費用。隨着商業化逐步展開，包括德克薩斯州的試點計劃和美國國防部爲進行持續研究購買的測試，該公司發展前景良好。肺癌篩查市場預計到2030年將達到57億美元。該公司的流式細胞術平台，輔以AI驅動的自動數據分析，正在開發用於非侵入性診斷COPD和哮喘的輔助診療工具，這兩者的全球市場總價值預計將在2027年達到82億美元。該公司擁有廣泛的美國和國際專利。內部人士對該公司的支持較強，持股比例爲39%，並在不斷增長。憑藉高度經驗豐富的領導團隊，bioAffinity Technologies有望在早期癌症診斷中推動創新。
About Biotricity
關於Biotricity
Biotricity is transforming the healthcare market by bridging the gap in remote monitoring and chronic care management with a focus on cardiology. Physicians and patients trust Biotricity's unparalleled standard for preventive and personal care, including diagnostic and post-diagnostic solutions for chronic conditions. The company develops comprehensive remote health monitoring solutions for the medical and consumer markets. To learn more, visit and follow us on Twitter and LinkedIn.
Biotricity正在通過實現遙測與慢性病管理之間的進一步連接，集中於心臟學領域，以此來改變保健市場。醫生和病人都信任Biotricity的預防性護理和個人護理的卓越標準，包括針對慢性疾病的診斷和後診斷解決方案。該公司開發了全面的面向醫療和消費市場的遠程健康監測解決方案。詳情請訪問，同樣您也可以關注我們的 Twitter 和 LinkedIn。
About bioAffinity Technologies, Inc.
關於bioAffinity Technologies, Inc.
bioAffinity Technologies, Inc. addresses the need for noninvasive diagnosis of early-stage cancer and diseases of the lung and broad-spectrum cancer treatments. The Company's first product, CyPath Lung, is a noninvasive test that has shown high sensitivity, specificity and accuracy for the detection of early-stage lung cancer. CyPath Lung is marketed as a Laboratory Developed Test (LDT) by Precision Pathology Laboratory Services, a subsidiary of bioAffinity Technologies. Research and optimization of the Company's platform technologies are conducted in its laboratories at Precision Pathology and The University of Texas at San Antonio. For more information, visit and follow us on LinkedIn, Facebook and X.
bioAffinity Technologies，Inc.致力於爲早期癌症和肺部疾病以及廣譜癌症治療提供無創診斷。該公司的第一款產品CyPath Lung是一種無創檢測方法，可以高靈敏度、特異性和準確性地檢測早期肺癌。 CyPath Lung由bioAffinity Technologies子公司Precision Pathology實驗室開發並作爲實驗室開發的檢測方法（LDT）銷售。該公司的平台技術研究和優化都在Precision Pathology和The University of Texas at San Antonio的實驗室中進行。欲了解更多信息，請訪問網站並在LinkedIn、Facebook和X上關注我們。
About RedChip Companies
關於RedChip公司
RedChip Companies, an Inc. 5000 company, is an international investor relations, media, and research firm focused on microcap and small-cap companies. For 32 years, RedChip has delivered concrete, measurable results for its clients. Our newsletter, Small Stocks, Big Money, is delivered online weekly to 60,000 investors. RedChip has developed the most comprehensive service platform in the industry for microcap and small-cap companies. These services include the following: a worldwide distribution network for its stock research; retail and institutional roadshows in major U.S. cities; outbound marketing to stock brokers, RIAs, institutions, and family offices; a digital media investor relations platform that has generated millions of unique investor views; investor webinars and group calls; a television show, Small Stocks, Big Money, which airs weekly on Bloomberg US; TV commercials in local and national markets; corporate and product videos; website design; and traditional investor relation services, which include press release writing, development of investor presentations, quarterly conference call script writing, strategic consulting, capital raising, and more.
RedChip公司是一家國際投資關係、媒體和研究公司，專注於微型股和小型股公司。30多年來，RedChip爲客戶提供了具體的、可量化的結果。我們的每週在線報告《Small Stocks，Big Money》每週在線投資者共計60,000人。RedChip已經發展成爲行業中最全面的服務平台，爲微型庫存和小型庫存提供以下服務：爲其股票調查提供遍佈全球的分銷網絡；在美國主要城市進行零售和機構路演；對股票經紀人、RIA、機構和家族辦公室進行出口推廣；數字媒體投資者關係平台，已經產生了數百萬獨特的投資者瀏覽量；爲投資者舉辦網絡研討會和小組電話；電視節目《Small Stocks, Big Money》每週在Bloomberg US播出，本地和全國市場的電視廣告；公司和產品視頻；網站設計；和傳統的投資者關係服務，包括新聞稿撰寫、投資者演示文稿開發、季度電話會議劇本撰寫、戰略諮詢、籌資等。
To learn more about RedChip's products and services, please visit:
要了解更多有關RedChip的產品和服務的信息，請訪問：
"Discovering Tomorrow's Blue Chips Today"
“發現明日的藍籌股”
Follow RedChip on LinkedIn:
在LinkedIn上關注RedChip：
Follow RedChip on Facebook:
在Facebook上關注RedChip：
Follow RedChip on Instagram:
在Instagram上關注RedChip：
Follow RedChip on Twitter:
在Twitter上關注RedChip：
Follow RedChip on YouTube:
在YouTube上關注RedChip：
Follow RedChip on Rumble:
在Rumble上關注RedChip：
Subscribe to our Mailing List:
訂閱我們的郵件列表：
Contact:
聯繫方式：
Dave Gentry
RedChip Companies Inc.
1-407-644-4256
info@redchip.com
Dave Gentry
RedChip Companies Inc.
1-407-644-4256
info@redchip.com
SOURCE: RedChip
來源：RedChip
譯文內容由第三人軟體翻譯。